Currently, there are 257.80M common shares owned by the public and among those 257.08M shares have been available to trade.
The company’s stock has a 5-day price change of -0.53% and -29.22% over the past three months. OGN shares are trading -24.66% year to date (YTD), with the 12-month market performance down to -37.07% lower. It has a 12-month low price of $10.45 and touched a high of $23.10 over the same period. OGN has an average intraday trading volume of 3.63 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -11.95%, -21.25%, and -34.14% respectively.
Institutional ownership of Organon & Co (NYSE: OGN) shares accounts for 81.93% of the company’s 257.80M shares outstanding.
It has a market capitalization of $2.90B and a beta (3y monthly) value of 0.85. The stock’s trailing 12-month PE ratio is 3.37, while the earnings-per-share (ttm) stands at $3.33. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.92% over the week and 6.15% over the month.
Earnings per share for the fiscal year are expected to decrease by -6.45%, and 3.88% over the next financial year. EPS should grow at an annualized rate of -0.16% over the next five years, compared to -23.49% over the past 5-year period.
Looking at the support for the OGN, a number of firms have released research notes about the stock. JP Morgan stated their Underweight rating for the stock in a research note on September 06, 2024, with the firm’s price target at $18-$20. Goldman coverage for the Organon & Co (OGN) stock in a research note released on November 03, 2023 offered a Neutral rating with a price target of $16. Barclays was of a view on September 21, 2023 that the stock is Overweight, while Raymond James gave the stock Outperform rating on March 16, 2023, issuing a price target of $33. BofA Securities on their part issued Underperform rating on October 14, 2022.
